A monoclonal antibody against αVβ3 integrin inhibits development of atherosclerotic lesions in diabetic pigs

Science Translational Medicine

Volumn 2, Issue 18, 2010, Pages

  Maile, Laura A ^a   Busby, Walker H ^a   Nichols, Timothy C ^a   Bellinger, Dwight A ^b   Merricks, Elizabeth P ^a   Rowland, Michael ^a   Veluvolu, Umadevi ^a   Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA3 INTEGRIN BETA SUBUNIT ANTIBODY F(AB) FRAGMENT; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PROTEIN SHC; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; FEMORAL ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; ANIMAL; CELL CULTURE; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; SWINE; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; FEMORAL ARTERY; IMMUNOGLOBULIN FAB FRAGMENTS; INSULIN-LIKE GROWTH FACTOR I; INTEGRIN ALPHAVBETA3; MALE; MICE; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SWINE; TIME FACTORS;

EID: 77953073611     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000476     Document Type: Article

References (51)

1. J. J. Bax, L. H. Young, R. L. Frye, R. O. Bonow, E. J. Steinberg; ADA, Screening for coronary artery disease in patients with diabetes. Diabetes Care 30, 2729-2736 (2007).
2. D. P. Mikhailidis, M. Press, The importance of treating multiple cardiometabolic risk factors in patients with type 2 diabetes. Expert Opin. Pharmacother. 8, 3009-3020 (2007).
3. B. Zhu, G. Zhao, D. P. Witte, D. Y. Hui, J. A. Fagin, Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury. Endocrinology 142, 3598-3606 (2001).
4. T. C. Nichols, W. H. Busby Jr., E. Merricks, J. Sipos, M. Rowland, K. Sitko, D. R. Clemmons, Protease-resistant insulin-like growth factor (IGF)-binding protein-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia. Endocrinology 148, 5002-5010 (2007).
5. P. Delafontaine, Y. H. Song, Y. Li, Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler. Thromb. Vasc. Biol. 24, 435-444 (2004).
6. S. C. Harrington, R. D. Simari, C. A. Conover, Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet. Circ. Res. 100, 1696-1702 (2007).
7. J. I. Pulai, M. Del Carlo Jr., R. F. Loeser, The α5β1 integrin provides matrix survival signals for normal and osteoarthritic human articular chondrocytes in vitro. Arthritis Rheum. 46, 1528-1535 (2002).
8. J. Zhong, J. Deng, J. Phan, W. Dlouhy, H. Wu, W. Yao, P. Ye, A. J. D'Ercole, W. H. Lee, Insulin-like growth factor-I protects granule neurons from apoptosis and improves ataxia in weaver mice. J. Neurosci. Res. 80, 481-490 (2005).
9. 3 integrin expression in normal and atherosclerotic artery. Circ. Res. 77, 1129-1135 (1995).
10. C. M. Giachelli, N. Bae, M. Almeida, D. T. Denhardt, C. E. Alpers, S. M. Schwartz, Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 92, 1686-1696 (1993).
11. S. Bhattacharyya, T. E. Marinic, I. Krukovets, G. Hoppe, O. I. Stenina, Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose. J. Biol. Chem. 283, 5699-5707 (2008).
12. S. Mori, M. Takamoto, K. Yokote, S. Asaumi, Y. Saito, Hyperglycemia-induced alteration of vascular smooth muscle phenotype. J. Diabetes Complications 16, 65-68 (2002).
13. J. I. Jones, T. Prevette, A. Gockerman, D. R. Clemmons, Ligand occupancy of the α-V-β3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc. Natl. Acad. Sci. U.S.A. 93, 2482-2487 (1996).
14. L. A. Maile, B. E. Capps, Y. Ling, G. Xi, D. R. Clemmons, Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinology 148, 2435-2443 (2007).
15. B. Zheng, D. R. Clemmons, Blocking ligand occupancy of the αVβ3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A. 95, 11217-11222 (1998).
16. S. S. Srivatsa, L. A. Fitzpatrick, P. W. Tsao, T. M. Reilly, D. R. Holmes Jr., R. S. Schwartz, S. A. Mousa, Selective αvβ3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin αvβ3 and osteopontin expression during neointima formation. Cardiovasc. Res. 36, 408-428 (1997).
17. T. C. Nichols, T. du Laney, B. Zheng, D. A. Bellinger, G. A. Nickols, W. Engleman, D. R. Clemmons, Reduction in atherosclerotic lesion size in pigs by αVβ3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling. Circ. Res. 85, 1040-1045 (1999).
18. S. Maubant, D. Saint-Dizier, M. Boutillon, F. Perron-Sierra, P. J. Casara, J. A. Hickman, G. C. Tucker, E. Van Obberghen-Schilling, Blockade of αVβ3 and αVβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 108, 3035-3044 (2006).
19. D. Monleón, V. Esteve, H. Kovacs, J. J. Calvete, B. Celda, Conformation and concerted dynamics of the integrin-binding site and the C-terminal region of echistatin revealed by homonuclear NMR. Biochem. J. 38, 57-66 (2005).
20. 2+ binding site on the β3-integrins that regulates the dissociation rate for RGD ligands. J. Biol. Chem. 271, 21745-21751 (1996).
21. 184 sequence of the β3-subunit of αVβ3. Mol. Endocrinol. 20, 405-413 (2006).
22. J. P. Xiong, T. Stehle, R. Zhang, A. Joachimiak, M. Frech, S. L. Goodman, M. A. Arnaout, Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 296, 151-155 (2002).
23. L. A. Maile, W. H. Busby, K. Sitko, B. E. Capps, T. Sergent, J. Badley-Clarke, Y. Ling, D. R. Clemmons, The heparin binding domain of vitronectin is the region that is required to enhance insulin-like growth factor-I signaling. Mol. Endocrinol. 20, 881-892 (2006).
24. E. T. Choi, M. F. Khan, J. E. Leidenfrost, E. T. Collins, K. P. Boc, B. R. Villa, D. V. Novack, W. C. Parks, D. R. Abendschein, b3-Integrin mediates smooth muscle cell accumulation in neointima after carotid ligation in mice. Circulation 109, 1564-1569 (2004).
25. 3 Integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells. Circulation 97, 907-915 (1998).
26. M. F. Janat, W. S. Argraves, G. Liau, Regulation of vascular smooth muscle cell integrin expression by transforming growth factor β1 and by platelet-derived growth factor-BB. J. Cell. Physiol. 151, 588-595 (1992).
27. R. Blindt, A. K. Bosserhoff, U. Zeiffer, N. Krott, P. Hanrath, J. vom Dahl, Abciximab inhibits the migration and invasion potential of human coronary artery smooth muscle cells. J. Mol. Cell. Cardiol. 32, 2195-2206 (2000).
28. E. J. Topol, A. M. Lincoff, D. J. Kereiakes, N. S. Kleiman, E. A. Cohen, J. Ferguson, J. E. Tcheng, S. Sapp, R. M. Califf, Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am. J. Med. 113, 1-6 (2002).
29. Q. Huang, N. Sheibani, High glucose promotes retinal endothelial cell migration through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am. J. Physiol. Cell Physiol. 295, C1647-C1657 (2008).
30. A. Ning, J. Cui, D. Maberley, P. Ma, J. Matsubara, Expression of integrins in human proliferative diabetic retinopathy membranes. Can. J. Ophthalmol. 43, 683-688 (2008).
31. 3-integrin, and TGF-β1 in response to ANG II and high glucose. Am. J. Physiol. Heart Circ. Physiol. 295, H69-H76 (2008).
32. C. P. Sodhi, S. A. Phadke, D. Batlle, A. Sahai, Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: Role of osteopontin. Am. J. Physiol. Renal Physiol. 280, F667-F674 (2001).
33. N. A. Wahab, L. Schaefer, B. S. Weston, O. Yiannikouris, A. Wright, A. Babelova, R. Schaefer, R. M. Mason, Glomerular expression of thrombospondin-1, transforming growth factor β and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48, 2650-2660 (2005).
34. R.S. Danda, N.M.Habiba, H. Rincon-Choles, B. K. Bhandari, J. L. Barnes, H. E. Abboud, P. E. Pergola, Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int. 68, 2562-2571 (2005).
35. S. Bhattacharyya, T. E. Marinic, I. Krukovets, G. Hoppe, O. I. Stenina, Cell type-specific post-transcriptional regulation of production of the potent antiangiogenic and proatherogenic protein thrombospondin-1 by high glucose. J. Biol. Chem. 283, 5699-5707 (2008).
36. Y. Ling, L. A. Maile, D. R. Clemmons, Tyrosine phosphorylation of the β3-subunit of the αVβ3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor. Mol. Endocrinol. 17, 1824-1833 (2003).
37. C. P. Sodhi, S. A. Phadke, D. Batlle, A. Sahai, Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells: Potentiation by high glucose. Diabetes 50, 1482-1490 (2001).
38. M. Campbell, W. E. Allen, J. A. Silversides, E. R. Trimble, Glucose-induced phosphatidylinositol 3-kinase and mitogen-activated protein kinase-dependent upregulation of the platelet-derived growth factor-β receptor potentiates vascular smooth muscle cell chemotaxis. Diabetes 52, 519-526 (2003).
39. B. Cercek, M. C. Fishbein, J. S. Forrester, R. H. Helfant, J. A. Fagin, Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ. Res. 66, 1755-1760 (1990).
40. M. Khorsandi, J. A. Fagin, M. C. Fishbein, J. S. Forrester, B. Cercek, Effects of hypophysectomy on vascular insulin-like growth factor-I gene expression after balloon denudation in rats. Atherosclerosis 93, 115-122 (1992).
41. M. B. Grant, T. J. Wargovich, E. A. Ellis, S. Caballero, M. Mansour, C. J. Pepine, Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis? Circulation 89, 1511-1517 (1994).
42. J. Du, T. Peng, K. J. Scheidegger, P. Delafontaine, Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler. Thromb. Vasc. Biol. 19, 2119-2126 (1999).
43. P. Häyry, M. Myllärniemi, E. Aavik, S. Alatalo, P. Aho, S. Yilmaz, A. Räisänen-Sokolowski, G. Cozzone, B. A. Jameson, R. Baserga, Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J. 9, 1336-1344 (1995).
44. L. M. Garcia-Segura, A. Sanz, P. Mendez, Cross-talk between IGF-I and estradiol in the brain: Focus on neuroprotection. Neuroendocrinology 84, 275-279 (2006).
45. M. Wittman, J. Carboni, R. Attar, B. Balasubramanian, P. Balimane, P. Brassil, F. Beaulieu, C. Chang, W. Clarke, J. Dell, J. Eummer, D. Frennesson, M. Gottardis, A. Greer, S. Hansel, W. Hurlburt, B. Jacobson, S. Krishnananthan, F. Y. Lee, A. Li, T. A. Lin, P. Liu, C.Ouellet, X. Sang, M. G. Saulnier, K. Stoffan, Y. Sun, U. Velaparthi, H. Wong, Z. Yang, K. Zimmermann, M. Zoeckler, D. Vyas, Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J. Med. Chem. 48, 5639-5643 (2005).
46. Y. Li, Y. Higashi, H. Itabe, Y. H. Song, J. Du, P. Delafontaine, Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler. Thromb. Vasc. Biol. 23, 2178-2184 (2003).
47. A. Gockerman, T. Prevette, J. I. Jones, D. R. Clemmons, Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology 136, 4168-4173 (1995).
48. K. Bonroy, F. Frederix, G. Reekmans, E. Dewolf, R. De Palma, G. Borghs, P. Declerk, B. Goddeeris, Comparison of random and oriented immobilisation of antibody fragments on mixed self-assembled monolayers. J. Immunol. Methods 312, 167-181 (2006).
49. T. J. Nam, W. H. Busby Jr., C. Rees, D. R. Clemmons, Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology 141, 1100-1106 (2000).
50. T. R. Griggs, R. W. Bauman, R. L. Reddick, M. S. Read, G. G. Koch, M. A. Lamb, Development of coronary atherosclerosis in swine with severe hypercholesterolemia. Lack of influence of von Willebrand factor or acute intimal injury. Arteriosclerosis 6, 155-165 (1986).
51. R. G. Gerrity, R. Natarajan, J. L. Nadler, T. Kimsey, Diabetes-induced accelerated atherosclerosis in swine. Diabetes 50, 1654-1665 (2001).